Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3746 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Mylan gets tentative OK for generic Zofran

Ondansetron orally disintegrating tablets are the generic version of GlaxoSmithKline's Zofran tablets, which had US sales of approximately $314 million for the same strengths for the 12-month period

Threshold cancer drug fails to meet study goal

Glufosfamide did not show a statistically significant improvement in overall survival compared to best supportive care in patients with pancreatic cancer who had relapsed after gemcitabine chemotherapy. While

Roche, Kosan initiate phase II cancer program

The epothilone compound, known as R1645, was well tolerated and demonstrated antitumor activity against ovarian and non-small cell lung cancers in a phase I trial. Epothilones are anticancer

King completes acquisition of pain drug

Avinza is indicated as a once-daily morphine treatment for chronic moderate-to-severe pain in patients who require continuous opioid therapy for an extended period of time. “The addition of

VGX signs merger agreement with ADViSYS

All acquired assets of ADViSYS, including its significant pipeline for DNA delivered therapeutics as well as DNA delivery and cGMP manufacturing capabilities will be added to VGX Pharmaceuticals'

Azur Pharma completes Pharmelle acquisition

Pharmelle markets branded prescription pharmaceutical products with a focus on the urology and female health markets. Pharmelle has a nationwide sales and marketing infrastructure in the US with